Medicare to pay for Avastin regardless of FDA

July 29, 2020

The Centers of Medicare and Medicaid said that Medicare will continue to pay for Avastin when it is prescribed to treat metastatic breast cancer, regardless of what the FDA would decide.

Stanford Study Shows Stem Cell Treatment Improves survival of Patients With Metastatic Breast Cancer

July 25, 2020

By Lea Steakley

Treating Stage IV breast cancer patients with high-dose chemotherapy followed by a rescue with their own, specially purified blood stem cells that had been purged of cancer, could significantly increase their chances of survival, according to new research from Stanford.

Categorization of Triple-Negative Breast Cancer Patients Will Help in Targeted Therapy Selection

July 13, 2020

By Anna Azvolinsky, PhD

Researchers at the Vanderbilt-Ingram Cancer Center and the Vanderbilt University School of Medicine have parsed the large and heterogeneous triple-negative breast cancer (TNBC) category of patients into 6 molecularly distinct subgroups.

Cancer vaccine firm Immunophotonics wants clinical trials within six months

July 11, 2020

By Deanna Pogorelc

A Missouri biotech company developing a laser-guided cancer vaccine therapy is raising money to get into clinical trials by the end of the year. Immunophotonics has so far focused its laser-assisted immunotherapy, called inCVAX, primarily on breast cancer treatment. The two-step device and drug process attacks late-stage metastatic cancer.

Everolimus Trial Stopped for Benefit in Breast Cancer

July 6, 2020

By John Gever

A phase III trial of everolimus (Afinitor) in locally advanced or metastatic breast cancer has been halted after an interim analysis indicated that the study's primary endpoint -- a significant difference in progression-free survival relative to a control therapy after six weeks -- was met, the drug's manufacturer said.

Medicare to Keep Paying for Avastin

July 5, 2020

By Emily P. Walker

Medicare will continue to pay for bevacizumab (Avastin) when it's used to treat metastatic breast cancer, even if the FDA decides to remove that indication from the drug, a spokesman for the Centers for Medicare and Medicaid Services (CMS) said.